New lifestyle drugs and somatoform disorders in dermatology

被引:8
作者
Harth, W. [1 ]
Seikowski, K. [2 ]
Hermes, B. [1 ]
Gieler, U. [3 ]
机构
[1] Med Univ Berlin, Charite, Acad Teaching Hosp, Clin Skin Dis,Vivantes Berlin Friedrichain, Berlin, Germany
[2] Univ Leipzig, Dermatol Clin, Leipzig, Germany
[3] Univ Giessen & Marburg, Clin Psychosomat & Psychotherapy, Marburg, Germany
关键词
body dysmorphic disorder; botulinum toxin; hypochondria; isotretinoin; lifestyle drugs; somatoform;
D O I
10.1111/j.1468-3083.2007.02507.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 [皮肤病与性病学];
摘要
An increasing number of healthy individuals make use of 'lifestyle' drugs, such as nootropics, psychopharmaca, hormones and eco-drugs. In this respect, the fact that many people try to improve their outer appearance, solve their I cosmetic problems', influence their rate of hair growth and altogether delay, halt or even reverse the natural ageing process has become a relevant matter for the practising dermatologist. Lifestyle drugs in dermatology are taken in an attempt to increase personal life quality by means of attaining a certain, psychosocially defined beauty ideal. They are not taken to manage a medically identifiable, well-defined disease. Often, patients suffering from somatoform disorders, such as hypochondriac disorders, body dysmorphic disorders, somatization disorders or persistent somatoform pain disorders, may spontaneously ask physicians, in particular dermatologists and plastic surgeons, to prescribe them lifestyle drugs. Typically, patients repeatedly present with alleged 'physical symptoms' that turn out to be subjective complaints without any underlying identifiable medical disease. The use of lifestyle drugs without any proper medical indication may lead to a chronification of the emotional disorders that had ultimately been the cause of the patients' request for such drugs. Such disorders may need to be treated promptly with psychotherapy and/or appropriate psychopharmacotherapy, and the choice of the treatment requires an accurate differential diagnostic approach.
引用
收藏
页码:141 / 149
页数:9
相关论文
共 68 条
[1]
The diagnosis and management of benzodiazepine dependence [J].
Ashton, H .
CURRENT OPINION IN PSYCHIATRY, 2005, 18 (03) :249-255
[2]
Demand, appropriateness and prescribing of 'lifestyle drugs': a consultation survey in general practice [J].
Ashworth, M ;
Clement, S ;
Wright, M .
FAMILY PRACTICE, 2002, 19 (03) :236-241
[3]
EXPERT-KILLER SYNDROME [J].
BECK, D .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1977, 102 (09) :303-307
[4]
Bella Anthony J, 2006, Can J Urol, V13, P3233
[5]
Prevalence of symptoms of body dysmorphic disorder and its correlates: A cross-cultural comparison [J].
Bohne, A ;
Keuthen, NJ ;
Wilhelm, S ;
Deckersbach, T ;
Jenike, MA .
PSYCHOSOMATICS, 2002, 43 (06) :486-490
[6]
Bozzola E, 2004, Minerva Pediatr, V56, P349
[7]
Brosig B, 2001, INT J CLIN PHARM TH, V39, P279
[9]
Modeling and simulation of sexual activity daily diary data of patients with female sexual arousal disorder treated with sildenafil citrate (Viagra®) [J].
Claret, Laurent ;
Cox, Eugene H. ;
McFadyen, Lynn ;
Pidgen, Alwyn ;
Johnson, Patrick J. ;
Haughie, Scott ;
Boolell, Mitra ;
Bruno, Rene .
PHARMACEUTICAL RESEARCH, 2006, 23 (08) :1756-1764
[10]
Quality-of-life drugs? [J].
Coons, SJ ;
Motheral, BR .
CLINICAL THERAPEUTICS, 2000, 22 (06) :773-774